Business Context and Reporting Period
Tenon Medical, Inc. (TNON) is a medical device company focused on treating sacroiliac (SI) joint disorders. The company markets two systems: The Catamaran System (FDA cleared in 2018) and the SImmetry+ System (acquired in August 2025). This Form 10-Q covers the quarterly period ended March 31, 2026. The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $1,379,000 | $726,000 |
| Gross Profit | $945,000 | $323,000 |
| Gross Margin | 69% | 44% |
| Net Loss | $(3,476,000) | $(3,616,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.31) | $(1.01) |
| Cash and Cash Equivalents (End of Period) | $4,607,000 | $10,311,000 |
| Net Cash Used in Operating Activities | $(2,960,000) | $(2,483,000) |
| Convertible Notes (Current Liability) | $3,480,000 | $0 |
| Derivative Liability | $608,000 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 90% year-over-year to $1.379 million, driven by an increase in surgical procedures and the inclusion of revenue from the newly acquired SImmetry+ System.
- Margin Expansion: Gross margin improved significantly from 44% to 69% due to operating leverage and the absorption of production overhead costs.
- Debt Financing: In March 2026, the company issued approximately $5.2 million in principal of 20% OID senior convertible promissory notes, receiving gross proceeds of $4.3 million. This resulted in a new current liability of $3.48 million and a derivative liability of $608,000.
- Operating Expenses: Total operating expenses increased 6% to $4.225 million. Sales and marketing expenses rose 13% due to higher payroll and commissions, while R&D expenses decreased 4% primarily due to lower stock-based compensation.
- Liquidity: Cash balances decreased from $10.3 million in Q1 2025 to $4.6 million in Q1 2026, despite financing inflows, due to continued operating losses.
Outlook, Risks, and Contingencies
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for one year from the filing date. Existing cash is insufficient to fund operations for the next 12 months, necessitating additional capital raises via equity or debt.
- Nasdaq Compliance: The company received a notice from Nasdaq on February 25, 2026, regarding failure to maintain the $1.00 minimum bid price. The company has an 180-day compliance period (until August 24, 2026) to regain compliance or face potential delisting.
- Internal Controls: The company identified a material weakness in internal controls over financial reporting due to a lack of segregation of duties, concluding that disclosure controls are not effective.
- Contingent Consideration: The company holds a liability of $960,000 related to royalties and future warrant exercises from the SiVantage/SIMPL acquisition.
- Subsequent Event: In April 2026, the company reached a $1 million sales milestone for the acquired products, triggering the issuance of 276,228 shares of common stock to the sellers on May 1, 2026.
Investor Verification Checklist
- Verify the company's ability to raise additional capital to address the "substantial doubt" regarding its going concern status.
- Monitor the stock price to ensure compliance with Nasdaq's $1.00 minimum bid price requirement by August 24, 2026.
- Review the terms of the new convertible notes issued in March 2026, specifically the 20% OID, maturity date (September 2026), and conversion mechanics.
- Assess the impact of the material weakness in internal controls on future financial reporting reliability.
- Track the commercial performance of the SImmetry+ System to validate the revenue growth trajectory.